Trial intelligence / Profile preview

Immunomodulating and neuroprotective properties of autologous mesenchymal stem cells in multiple sclerosis

2012-000518-13Phase 2Completed

Sponsor: Prof. Per Soelberg SÃ¸rensen
Start: Jun 2012
Modality: Stem Cell Therapies → Cell Therapies
Countries: 1

Overview

Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing Early MSCs with Late MSCs / Placebo first (2 arms). Primary endpoint: Combined unique MRI lesion activity at 24 weeks. Started Jun 2012; status: completed.

Drugs

mesenchymal stem cells

Conditions

multiple sclerosis (MS)

Beyond the preview

Go deeper on 2012-000518-13.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-000518-13.